Vanguard Group Inc. boosted its holdings in shares of Trevena, Inc. (NASDAQ:TRVN) by 15.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,822,103 shares of the biopharmaceutical company’s stock after purchasing an additional 238,089 shares during the quarter. Vanguard Group Inc. owned approximately 3.13% of Trevena worth $4,191,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of TRVN. American International Group Inc. boosted its position in Trevena by 7.1% during the first quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 1,816 shares in the last quarter. Nationwide Fund Advisors raised its holdings in shares of Trevena by 92.1% during the second quarter. Nationwide Fund Advisors now owns 49,132 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 23,557 shares during the last quarter. Bourgeon Capital Management LLC raised its holdings in shares of Trevena by 56.8% during the second quarter. Bourgeon Capital Management LLC now owns 53,031 shares of the biopharmaceutical company’s stock valued at $122,000 after acquiring an additional 19,200 shares during the last quarter. Alliancebernstein L.P. raised its holdings in shares of Trevena by 51.9% during the second quarter. Alliancebernstein L.P. now owns 55,300 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 18,900 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Trevena by 30.1% during the second quarter. Rhumbline Advisers now owns 64,251 shares of the biopharmaceutical company’s stock valued at $148,000 after acquiring an additional 14,880 shares during the last quarter. Institutional investors own 56.27% of the company’s stock.

Shares of Trevena, Inc. (NASDAQ TRVN) opened at $1.65 on Friday. Trevena, Inc. has a fifty-two week low of $1.35 and a fifty-two week high of $8.00. The company has a current ratio of 4.92, a quick ratio of 4.92 and a debt-to-equity ratio of 0.38.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.06. During the same period last year, the firm posted ($0.57) earnings per share. research analysts predict that Trevena, Inc. will post -1.25 EPS for the current fiscal year.

A number of equities analysts have commented on TRVN shares. Zacks Investment Research raised Trevena from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a report on Wednesday, October 18th. Needham & Company LLC reduced their target price on Trevena from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, November 8th. HC Wainwright reduced their target price on Trevena from $8.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, October 12th. Barclays cut Trevena from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $15.00 to $2.50 in a report on Monday, October 16th. Finally, Oppenheimer set a $5.00 target price on Trevena and gave the company a “buy” rating in a report on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $8.09.

ILLEGAL ACTIVITY WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/trevena-inc-trvn-holdings-boosted-by-vanguard-group-inc/1740796.html.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Institutional Ownership by Quarter for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.